DGAP-News: Abattis Bioceuticals Corp

DGAP-News: Abattis Receives NPN from Health Canada for Phyto(NOS)(TM)

DGAP-News: Abattis Bioceuticals Corp. / Key word(s): Miscellaneous Abattis Receives NPN from Health Canada for Phyto(NOS)(TM)

12.04.2016 / 14:00 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Vancouver, British Columbia--(Newsfile Corp. - April 12, 2016) - Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) ('Abattis') is pleased to announce that it has received a Natural Product Number ('NPN') approval for Phyto(NOS)TM. This NPN allows Abattis to manufacture and to sell Phyto(NOS) TM in Canada. Ingredient Identity of Santa Ana, California, completed the claim substantiation report necessary for the sale of Phyto(NOS)TM in the United States. Phyto(NOS)TM is an all-natural, patent-pending formulation that naturally supports nitric oxide (a vasodilator) levels in the blood stream, supports nitric oxide production, and provides antioxidants that help protect against oxidative cell damage caused by free radicals. Phyto(NOS) TM has applications in a wide range of food, beverage and nutraceutical products. Abattis Director and product designer, Brazos Minshew, says 'I designed Phyto(NOS)TM to deliver bio-active Nitric Oxide to the body in a natural, sustainable and metabolically-friendly manner. Nitrates in the plant-based ingredients of PHYTO[NOS](tm) get converted quickly into nitric oxide. This action is faster and doesn't require enzymes. The benefits are seen with very small quantities of nitrates under conditions of both high and low oxygen.'He adds, 'In our NÖXX Botanical Blends [url: http://www.abattis.com/#!noxx-botanical-blends/bw0yv] line of products, PHYTO[NOS](tm) is blended with other natural fruit and herb extracts to target specific health concerns by enhancing the benefits and focusing the desired effects in each of our products.' Our market research and outreach within our target markets validates both the need and the demand for the NÖXX Botanical Blends line of products. Early interest from customers and other product developers interested in all-natural nitric oxide support has been very positive. The worldwide market for products where nitric oxide is involved in the mechanism of action is expected to reach US$147 billion in 2019.1 The discovery of the nitric oxide pathway is recognized as a critical advancement in cell signaling and has led to major advancements in many clinical areas that have the ability to transform biotechnology and medicine. Important therapeutic areas for nitric oxide-based therapies are inflammatory disorders, cardiovascular diseases, erectile dysfunction, inflammation, pain and neuroprotection. Decreased production and or bioavailability of nitric oxide is recognized as being one of the earliest events in the onset and progression of many diseases.2 ON BEHALF OF THE BOARD 'Rene David' Rene David, CFO For further information, contact the Company at (604) 336-0881 or at news@abattis.com. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. FORWARD LOOKING INFORMATION This press release contains forward-looking statements. The use of any of the words 'anticipate', 'continue', 'estimate', 'expect', 'interest', 'may', 'will', 'project', 'should', 'believe' and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time. 1 Jain PharmaBiotech. Nitric Oxide: Therapeutics, Markets and Companies. Press Release (2010). www.researchandmarkets.com/reports/39078/nitric_oxide. 2 Nathan S Bryan, Nitric oxide enhancement strategies. Future Science OA. August 2015, Vol. 1, NO.1

Click on, or paste the following link into your web browser, to view the associated documents

http://www.newsfilecorp.com/release/20065

News Source: Newsfile

---------------------------------------------------------------------------

12.04.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English Company: Abattis Bioceuticals Corp. Canada ISIN: CA00258G1037 End of News DGAP News Service ---------------------------------------------------------------------------

453539 12.04.2016